Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | ADK | P55263 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 2/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17303458 | 0.93 | KDM4E (0.77) | ALDH1A1KDM4ENISCHMTORADK | |
| SCHEMBL1060312 | 0.84 | KDM4E (1.00) | ALDH1A1KDM4ENISCHMTORADK | |
| Hydrochloric Acid SCHEMBL3895818 | 0.83 | KDM4E (0.96) | ALDH1A1KDM4ENISCHMTORADK | |
| SCHEMBL27972616 | 0.83 | KDM4E (0.96) | ALDH1A1KDM4ENISCHMTORADK | |
| SCHEMBL7728112 | 0.80 | PTPN1 (0.61) | ALDH1A1KDM4ENISCHMTORADK | |
| SCHEMBL5148367 | 0.80 | NISCH (0.91) | ALDH1A1KDM4ENISCHMTORADK | |
| 2-Phenylimidazole SCHEMBL9719773 | 0.80 | NISCH (1.00) | ALDH1A1KDM4ENISCHMTORADK | |
| 2-Phenylimidazole SCHEMBL8901 | 0.80 | NISCH (1.00) | ALDH1A1KDM4ENISCHMTORADK | |
| SCHEMBL7383120 | 0.79 | KDM4E (0.72) | ALDH1A1KDM4ENISCHMTORADK | |
| SCHEMBL3634334 | 0.79 | KDM4E (0.72) | ALDH1A1KDM4ENISCHMTORADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | ALDH1A1 228/4885KDM4E 1370/4885NISCH 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.